The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VNDA | +64.24% | -46.78% | -11.85% | -23% |
| S&P | +19.32% | +83.47% | +12.91% | +441% |
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
This small-cap drugmaker just soared on positive clinical trial data, but should you jump on the bandwagon?
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $56.26M | 18.1% |
| Gross Profit | $51.55M | 18.9% |
| Gross Margin | 91.63% | 0.7% |
| Market Cap | $294.85M | 7.9% |
| Market Cap / Employee | $801.24K | 0.0% |
| Employees | 368 | 0.0% |
| Net Income | -$22,586.00K | -324.2% |
| EBITDA | -$29,231.00K | -223.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $70.02M | -30.3% |
| Accounts Receivable | $50.54M | 18.2% |
| Inventory | 2 | 26.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.23M | 13.5% |
| Short Term Debt | $4.69M | 91.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.51% | -11.0% |
| Return On Invested Capital | 1.93% | -6.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$31,787.00K | -115.6% |
| Operating Free Cash Flow | -$31,626.00K | -116.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.52 | 0.50 | 0.54 | 0.61 | 19.97% |
| Price to Sales | 1.41 | 1.33 | 1.37 | 1.39 | -2.88% |
| Price to Tangible Book Value | 0.66 | 0.63 | 0.70 | 0.78 | 22.04% |
| Enterprise Value to EBITDA | 9.99 | 1.55 | 0.97 | -0.41 | -103.91% |
| Return on Equity | -3.5% | -8.4% | -13.0% | -16.7% | 453.11% |
| Total Debt | $12.36M | $11.75M | $11.64M | $10.92M | 37.47% |
No podcast episodes available.
VNDA earnings call for the period ending September 30, 2021.
VNDA earnings call for the period ending June 30, 2021.
VNDA earnings call for the period ending December 31, 2020.
VNDA earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
